Vanda Pharmaceutical Inc. VNDA, +20.07% shares are up 18% in premarket trade after the biotech firm said late Monday it had settled licensing arbitration proceedings with Novartis AG NVS, +0.73% and will reacquire U.S. and Canadian rights to the schizophrenia treatment Fanapt.
Own it in my SI contest portfolio but not in real life
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.